Posted on

cbd oil and seizures

Cannabis oil for epilepsy

Published on 23 February 2020

Updated: 2 February 2021

Authored by Anonymous

Cannabis oil for epilepsy

On 1 November 2018, the Government’s landmark decision to reschedule some cannabis based products for medicinal use, came into force. The change in law means that specialist doctors in the UK can now prescribe medicinal cannabis to people with a limited number of conditions, including epilepsy. Here we explain what the change in law means for people with epilepsy.

What is cannabis?

Cannabis is made up of hundreds of different components. The most well known are two cannabinoids: CBD – cannabidiol – and THC – tetrahydrocannabinol. These are found naturally in the resin of the cannabis plant.

THC is the psychoactive compound in cannabis. It is responsible for the “high” people feel. The legal limit of THC content in a product, as stipulated by the Home Office, is 0.2%.

CBD is not psychoactive and it is thought to be responsible for many of the medical benefits associated with cannabis.

What is medicinal cannabis?

The Government has defined a cannabis-based product for medicinal use in humans as one that:

“Is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative; is produced for medicinal use in humans and is a medicinal product, or a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product”.

Guidance around prescribing cannabis-based products

In August 2019, NICE – the National Institute of Health and Clinical Excellence – announced that it would not be recommending that cannabidiol, a medicinal cannabis in the form of Epidyolex, should be prescribed on the NHS for children with two severe forms of epilepsy. This is on account of the fact that its long-term effect remains unclear.

The body also has concerns about the ‘viability of the economic model’ used by GW Pharma, the company that developed the drug, to establish the cost to be charged to the NHS for it. It concluded that Epidyolex would not, at this stage, be an effective use of NHS resources.

The recommended guidelines are still only draft and the consultation closes on 16 September. So there is still time for you to have your say and let them know what you think. Professor Sander will be doing the same. All comments received will be considered by NICE and final guidance is likely to be published in November 2019.

The British Paediatric Neurology Association (BPNA) has drawn up interim guidance around epilepsy on behalf of NHS England.

Guidance for other conditions is being drawn up the Royal College of Physicians with the Royal College of Radiologists (RCR) and the Faculty of Pain Medicine of the Royal College of Anaesthetists.

Guidance from the Association of British Neurologists (ABN)

Interim guidance from the ABN states that there is only published evidence for the use of medicial cannabis in Dravet syndrome and Lennox-Gastaut syndrome. Prescriptions should only be for cannabidiol.

Although the label Lennox-Gastaut is often broadly attached to severe epilepsies with compatible seizure types and intellectual disabilities, it is important that there is a clear syndromic diagnosis.

Dosing data for adults is currently very limited, although more information is expected shortly.

Guidance from the British Paediatric Neurology Association (BPNA)

The BPNA guidance states that non-licensed medicinal cannabis should only be considered for children who:

  • have an epilepsy that does not respond to conventional licensed anti-epileptic medications
  • have not responded to the ketogenic diet or who are not suitable for the ketogenic diet
  • who are not candidates for epilepsy surgery.

The BPNA states that the current best evidence for medicinal cannabis is CBD, a highly purified liquid, which has been licensed in the US by the Food and Drug Administration and is currently going through the application process for a licence from the European Medicines Agency.

CBD does not contain any significant amount of THC, the component of cannabis associated with producing a ‘high’.

What is the evidence?

The reason that the BPNA is only recommending CBD is that there is some evidence to show that this newly developed drug can be effective in reducing some type of seizures in Dravet and Lennox Gastaut syndromes.

Three double blind randomised controlled trials of pure CBD in children and young people with these syndromes has shown a greater reduction in monthly seizures compared to placebos. There was also a greater reduction in drop seizures in people taking CBD compared to those on a placebo. Further open label studies have shown that it may also have an anti-epileptic effect in the epilepsies in general.

What is the evidence around THC?

While some studies have also suggested that THC may have an anti-epileptic effect, animal studies suggest it can also trigger seizures. There is no evidence from randomised controlled clinical trials for products with higher proportions of THC (more than 0.2 per cent).

Concerns have also been raised about the effect of THC on the developing brain in children and young people. Evidence suggests that chronic exposure to THC can affect brain development, structure and mental health.

There is also no good scientific evidence to support suggestions that the addition of THC in combination with CBD increases the efficacy of cannabis-based medicinal products for children.

“Clinicians should not feel under pressure to prescribe cannabis-based medicinal products until they have undergone proper clinical trials,” says the BPNA.

“We recommend that these products undergo randomised clinical trials for efficacy and safety before they are routinely prescribed in the UK. We welcome the rescheduling of these products from Schedule 1 to Schedule 2 that will enable their investigation in clinical trials.”

Children already on products containing THC

The BPNA also recommends that where children are already taking other cannabis-based products that contain higher proportions of THC, they should be transitioned on to CBD until strong evidence for these products can be produced through clinical trials.

The Government has no plans to legalise the use of cannabis for recreational purposes. Possession of cannabis is illegal. This includes cannabis for medical use unless it has been prescribed for you.

Getting a prescription for medicinal cannabis

Cannabis-based medicinal products can only be prescribed by a specialist. A GP cannot prescribe the medication but could refer you to a specialist.

The specialist will discuss all other treatment options with you first before considering a cannabis-based product.

A prescription for medicinal cannabis would only be given when all other treatment options have been tried or are considered unsuitable, and would only be given if the doctor considers it to be in your best interests.

People always have the option of seeking a second opinion.

Health food shops

There is also a wide range of other cannabis products available on the internet and in some commercial outlets such as health food outlets and from cannabis ‘dispensaries’ internationally. These products are of unknown quality and contain CBD and THC in varying quantities and proportions.

MHRA is working with individual companies to ensure that CBD-based products that make medicinal claims should be licensed and meet safety, quality and efficacy standards to protect public health. To date, the MHRA has licensed no other cannabis based medicinal products as medicines.

With talk in the media about the use of cannabis products to treat epilepsy, generating interest…

Medical Marijuana and Epilepsy

Learn

Learn

In this episode of Hallway Conversations, epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Dr. Jose Cavazos MD, PhD, professor of neurology at the University of Texas Health Science Center in San Antonio. They discuss Dr. Cavazos’ experience serving as a panelist on the recent U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drug Advisory Committee review of Epidiolex ® for the treatment of Dravet and Lennox-Gastaut syndromes.

The Journal of Child Neurology hosted a special report podcast about cannabis on March 6, 2017. In the report, Dr. Alison Christy interviews Dr. Jackie Gofshteyn, a resident in pediatric neurology at Children’s Hospital of Philadelphia, about her article, “Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases.” Dr. Christy also speaks with epilepsy.com’s medical cannabis editor, Dr. Anup Patel of Nationwide Children’s Hospital, about his article, “Medical Marijuana in Pediatric Neurological Disorders.” Margo Roemeling, a third year medical student at Oregon Health and Sciences University, shares the learning topic on the history and use of marijuana in the treatment of pediatric neurologic conditions.

  • Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome, September 2018
  • Cannabis and Seizures: Questions to Consider, September 2018
  • Epilepsy Foundation Statement on the FDA’s Approval of Epidiolex, June 2018
  • Epilepsy Foundation Testifies Before FDA Advisory Committee in Support of Potential First-Ever Cannabidiol Drug to Treat Dravet Syndrome, April 2018
  • A Parent’s Perspective: the LGS Epidiolex Study, January 2018
  • Data on Purified CBD, Epidiolex, for Dravet Syndrome, May 2017
  • Cannabis & Seizures: Questions to Consider, March 2017

Join our mailing list to stay to date about programs, events, and news about epilepsy.

The use of cannabis to treat epilepsy and other neurological conditions has been studied for a number of years. It has been hotly debated too.

On June 25, 2018, the U.S. Food & Drug Administration (FDA) approved EPIDIOLEX ® (cannabidiol, CBD) oral solution for the treatment of seizures associated with two epilepsy syndromes – Lennox-Gastaut syndrome and Dravet syndrome – in people two years of age or older. Epidiolex represents a new medication option for children with these types of epilepsy. It is also the first ever FDA approved medication to treat seizures in Dravet syndrome.

What does FDA approval of Epidiolex (CBD oral solution) mean?

The FDA approval and Drug Enforcement Administration (DEA) scheduling of Epidiolex brings to market the first plant-based drug derived from the cannabis plant in the U.S.

Learn More

  • Statement on DEA Rescheduling Epidiolex
  • Q&A on the DEA Rescheduling of Epidiolex
  • Medical cannabis and CBD frequently asked questions
  • Medical cannabis and CBD advocacy

What is medical cannabis?

Cannabis is known by many names – the most common is marijuana. Cannabis is the Latin name used most often by botanists and pharmaceutical companies. The word marijuana usually refers to the leaves and female flowers of the cannabis plant. Medical cannabis is whole plant marijuana or chemicals in the plant used for medical purposes.

Cannabinoids are substances in cannabis that act on cells in the body (called cannabinoid receptors) to cause some effect. Two major ingredients include

  • Tetrahydrocannabinol, or THC, which causes the psychoactive effects of “getting high”
  • Cannabidiol, or CBD, which does not cause psychoactive effects but has shown some positive effects on certain body systems. This is the part that has been effective in reducing seizures in some people with epilepsy.

Does cannabis help seizures?

Early evidence from laboratory studies, anecdotal reports, and small clinical studies over a number of years suggest that cannabidiol (CBD) could potentially help control seizures. Research on CBD has been hard to do and taken time due to federal regulations and limited access to cannabidiol. There are also many financial and time constraints. In recent years, a number of studies have shown the benefit of specific plant-based CBD product in treating specific groups of people with epilepsy who have not responded to traditional therapies.

What do I need to know about hemp?

Hemp is a variety of Cannabis Sativa L. plant historically grown for fibrous materials found in its stalks and seeds. It has been used to make items such as clothing fiber, upholstery, and other household items.

Hemp traditionally contains lower concentrations of THC and higher levels of CBD. Cannabinoids extracted from hemp plants, including CBD, have until recently been classified as marijuana and considered Schedule I substances. Per the DEA, Schedule I substances currently have no accepted medical use and have a high potential for abuse. A federal law* enacted in December 2018, however, reclassifies hemp and hemp-derived CBD as an agricultural commodity and exempts it from the list of Schedule I Drugs.

Despite this change in the classification of hemp and hemp-derived CBD, the only CBD product that has been rigorously studied and approved to be used as a medical therapy for epilepsy is the drug Epidiolex. While more CBD products may come to market in the coming months, it is important to understand that not every CBD product is the same quality or uniform from batch to batch. Any drug or supplement that is being considered for use as a medical treatment should first be discussed with your doctor. The potential for benefit as well as the interaction with other seizure medications and possible side effects require careful review with your doctor.

*The Agriculture and Nutrition Act of 2018 (H.R. 2) legalizes hemp and hemp-derived CBD. The bill changes the definition of hemp to encompass any plant or product derived from the plant that contain less than 0.3% THC by dry weight and classifies them as exempt from the controlled substance restrictions applied to marijuana. The law further amends the Controlled Substances Act to exempt hemp from Schedule I drugs.

What studies exist to support the use of CBD in epilepsy?

Epidiolex (Cannabidiol, CBD)

Studies in the U.S. of Epidiolex (a plant-based CBD formulation) have been ongoing for a number of years. Data from these studies has helped provide evidence that led to the FDA approval of this product on June 25, 2018.

Epidiolex is a purified (> 98% oil-based) CBD extract from the cannabis plant. It is produced by Greenwich Biosciences (the U.S. based company of GW Pharmaceuticals) to give known and consistent amounts in each dose.

Researchers studied this medicine in controlled clinical trials. These studies used a control group with some people taking a placebo while others were given CBD at different doses. Researchers did not know who was getting the placebo and who was getting CBD. These tpyes of studies are called “gold standard” studies.

A summary of the Epidiolex clinical trials is found below:

  • In controlled and uncontrolled trials in people with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, 689 people were treated with Epidiolex (CBD), including 533 people treated for more than 6 months and 391 people treated for more than 1 year.
  • In an expanded access program and other compassionate use programs, 161 people with Dravet syndrome and LGS were treated with Epidiolex, including 109 people treated for more than 6 months.
  • All study participants were taking other seizure medications.
  • In controlled trials, the rate of stopping the medicine due to any side effect was small and happened most in people taking the higher dose of Epidiolex.
  • The most frequent cause of stopping treatment with Epidiolex was a change in liver function.
  • Sleepiness, sedation, and lethargy led to stopping Epidiolex in 3% of people taking the higher dose.
  • The most common side effects were sleepiness, decreased appetite, diarrhea, change in liver function, fatigue, malaise, asthenia (weakness or lack of energy), rash, insomnia, sleep disorder, poor quality sleep, and infections.

Results from Gold Standard Studies of Epidiolex (CBD)

NEJM May 2018

Summarized below are the results from a study published in the New England Journal of Medicine in May 2018.

  • Randomized double-blind, placebo-controlled trial (gold standard) was done at 30 clinical centers.
  • People with LGS (age range 2 to 55 years) who had had two or more drop (atonic) seizures each week during a 28-day baseline period were included. They were randomly selected to receive CBD oral solution at a dose of either 20 milligram per kilogram of body weight (20-mg cannabidiol group) or 10 milligram per kilogram of body weight (10-mg cannabidiol group) or matching placebo.
  • A total of 225 people were enrolled in the 3 groups:
    • 76 people were assigned to the 20-mg CBD group
    • 73 to the 10-mg CBD group
    • 76 to the placebo (no CBD) group
  • CBD was given to people twice a day for 14 weeks.
  • The researchers measured the percentage of change in drop seizures from baseline.
  • During the 28-day baseline period, the average number of drop seizures was 85 in all 3 groups combined.
  • During the treatment period, drop seizures decreased from baseline by:
    • 41.9% in the 20-mg CBD group
    • 37.2% in the 10-mg CBD group
    • 17.2% in the placebo group
  • The most common side effects in people taking cannabidiol were sleepiness, decreased appetite, and diarrhea. These happened more often in people taking the higher dose of CBD.
  • Only 6 people in the 20-mg CBD group and 1 person in the 10-mg CBD group stopped the study because of side effects.
  • 14 people who received CBD had an increase in a test of liver function. Many of these children were on valproic acid too.

This study showed that the addition of CBD to a traditional seizure medication decreased the frequency of drop seizures significantly in children and adults with LGS.

NEJM May 2017

Summarized below are results from the May 2017 New England Journal of Medicine study examining the effectiveness of Epidiolex (CBD) in people with drug resistant seizures with Dravet syndrome.

  • Randomized double-blind, placebo-controlled trial (gold standard) included 120 children and young adults with Dravet syndrome and drug-resistant seizures. They were randomly assigned to receive either CBD oral solution (20 milligrams per kilogram of body weight per day) or placebo.
  • CBD was given in addition to standard seizure medications.
  • The study measured the change in the number of convulsive seizures over the CBD treatment period, as compared to baseline period.
  • The percentage of people who had at least a 50% reduction in convulsive-seizure frequency was
    • 43% with cannabidiol
    • 27% with placebo
  • The frequency of total seizures of all types was significantly reduced with CBD, but there was no significant reduction in non-convulsive seizures.
  • The percentage of people who became seizure-free was 5% with CBD and 0% with placebo.
  • Adverse events that occurred more frequently in the CBD group than in the placebo group included diarrhea, vomiting, fatigue, fever, somnolence (sleepiness), and abnormal results on liver-function tests. There were more withdrawals from the trial in the cannabidiol group.

This study was able to show that among people with the Dravet syndrome, CBD resulted in a greater decrease in convulsive-seizures than placebo. It also showed that CBD was associated with higher rates of adverse events.

Additional Cannabidiol Studies

Results from 214 people who received Epidiolex (99% CBD) in an open-label study (without a placebo control) and who completed 12 weeks or more on the drug were published in 2015 in Lancet Neurology.

  • People who received Epidiolex ranged from 2 to 26 years old with an average age of 11.
  • All had epilepsy that did not respond to currently available treatments.
  • During the study, seizures decreased by an average of 54%.
  • People taking the anti-seizure medication clobazam (Onfi) seemed to have a better response when compared to those who were not on this medication.

An Israeli study using a product that had 20 parts of CBD to 1 part of THC was performed in an open-label format for children up to age 18 years with hard to control epilepsy. A significant number of people reported seizure reduction with 7% stating seizures worsened.

Are there ongoing CBD clinical trials?

A number of clinical trials are active and recruiting people, including studies using Epidiolex in people with Tuberous Sclerosis Complex and Sturge-Weber Syndrome.

Does cannabis have side effects?

Marijuana or cannabis in general has a number of side effects depending on how it is used. For example, if smoked, the negative effect of smoking on a person’s lungs and heart also apply to marijuana.

It is important to know that even though marijuana is a plant, it is broken down in a person’s liver like many medicines. People mistakenly believe that marijuana is completely safe because it is a plant or oil from a plant. However, medication interactions can occur.

The safety data from the trials in people with Lennox-Gastaut syndrome and Dravet syndrome has shown similar side effects. Tiredness, diarrhea, and upset stomach are reported the most. Interestingly, people getting the placebo also reported diarrhea and upset stomach feeling as well. This may be due to both products being oil.

Should I worry about drug interactions?

There are some drug-to-drug interactions that have been revealed during the studies of CBD in epilepsy syndromes. More research continues to be done examining these interactions. We know from studies that have been done:

  • People who had increases in their liver enzymes to a level three times or more than normal were also on valproic acid (VPA), a commonly used anti-seizure medication. The levels of VPA were not increased when taken with CBD. It is thought that a part or byproduct of VPA may interact with CBD when it is broken down. This may put some people at increased risk for liver issues.
  • As clobazam (Onfi) is broken down, a major component of the drug appears to interact with CBD in some people. This may be the cause of tiredness that is seen in some people who are on both CBD and Onfi.

What are the laws governing medical marijuana and cannabidiol?

The 2018 Farm Bill, signed into law by President Trump in December 2018, exempts hemp and hemp-derived products, including CBD, from the Controlled Substances Act. Previously, hemp-derivatives were classified as Schedule I cannabis products, meaning they had no acceptable medical use and had a high potential for abuse. The Farm Bill lifts federal restrictions surrounding CBD and legalizes the cultivation, manufacturing, and sale of these products across the United States. However, this does not mean that all hemp-derived products, including CBD, are medically appropriate.

Over half of U.S. states have laws allowing cannabis to be recommended and dispensed to people for medical reasons. The 2018 Farm Bill does not change existing laws surrounding state medical cannabis programs. Individuals who purchase treatments through a medical dispensary and via a recommendation from their physician are still required to follow the regulations set forth including registration, renewal of medical cards, and other requirements decided by each state.

In June 2018, the FDA approved Epidiolex allowing medical providers to prescribe this medication for Lennox-Gastaut and Dravet syndromes, similar to how they are able to prescribe other seizure medications. In late September 2018, the DEA rescheduled Epidiolex to Schedule V and all states and the District of Columbia have created pathways so that it can be brought to market for consumers. Read an FAQ to learn more.

Providers do not need a special license or certificate to prescribe Epidiolex. Epidiolex is the first and only plant-based treatment derived from cannabis for use as a treatment for seizures with FDA approval. Other formulations of medical cannabis have not been approved by the FDA.

Traveling with CBD Products

In May 2019, the Transportation Security Administration (TSA) updated its guidelines on traveling with CBD products. When you fly, you can now carry on or pack in checked baggage products/medications that contain hemp-derived CBD (with less than 0.3% THC) or are approved by the FDA, such as Epidiolex.

While the carry-on quantity of liquids is less than 3.4 ounces/100mL, TSA allows larger amounts of medically necessary liquids in reasonable quantities for your trip. However, you must declare them to security officers at the checkpoint for inspection. In checked baggage, liquid medications are allowed without packing requirements, quantity limitations, or notification requirements. Learn more on TSA’s website.

Should a person with epilepsy pursue medical cannabis if all other medications do not work?

When conventional treatments do not work to control seizures, as is the case for roughly 30% of people with epilepsy, it is not unreasonable to consider CBD oil. However, this should only be considered after a thorough evaluation at a specialized epilepsy center to look at whether all possible treatments (including FDA-approved new and add-on medicines, dietary therapy, devices, and surgery) have been reasonably tried.

The Epilepsy Foundation urges anyone exploring any treatment for their epilepsy, as permitted under their state law, to work with their treating physician to make the best decisions for their own care.

Where can I learn more?

Learn about the Epilepsy Foundation’s state and federal advocacy efforts on removing barriers to cannabis research and supporting access to medical cannabis (marijuana) in consultation with the treating physician.

  • What is medical cannabis?
  • What is CBD?
  • What is the Epilepsy Foundation’s position on medical cannabis and CBD?
  • What is the legal status of CBD?
  • What is the legal status of medical cannabis?
  • Are there any side effects or drug interactions associated with medical cannabis or CBD?
  • Will medical cannabis or CBD replace my other medications?
  • What do I do if my physician or prescribing provider will not recommend medical cannabis or CBD?
  • Is there any difference in the commercial-grade CBD I purchase online or from a health food store and the dispensary-grade CBD sold in medical dispensaries?
  • Are there currently any FDA-approved therapies derived from CBD?
  • How is Epidiolex ® different from commercial grade CBD sold over-the-counter and in dispensaries?

Find information about medical cannabis, including research on potential treatments for seizures, side effects, laws, and advocacy efforts.